Cho Yeoungjee, Hawley Carmel M, Johnson David W
Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia ; Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia.
Department of Renal Medicine, University of Queensland at Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia ; Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia ; Department of Nephrology, Princess Alexandra Hospital, Level 2, ARTS Building, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia.
Int J Nephrol. 2014;2014:909373. doi: 10.1155/2014/909373. Epub 2014 May 6.
Inflammation at both systemic and local intraperitoneal levels commonly affects peritoneal dialysis (PD) patients. Interest in inflammatory markers as targets of therapeutic intervention has been considerable as they are recognised as predictors of poor clinical outcomes. However, prior to embarking on strategies to reduce inflammatory burden, it is of paramount importance to define the underlying processes that drive the chronic active inflammatory status. The present review aims to comprehensively describe clinical causes of inflammation in PD patients to which potential future strategies may be targeted.
全身和局部腹膜内水平的炎症通常会影响腹膜透析(PD)患者。炎症标志物作为治疗干预靶点备受关注,因为它们被认为是临床预后不良的预测指标。然而,在着手采取策略减轻炎症负担之前,明确导致慢性活动性炎症状态的潜在过程至关重要。本综述旨在全面描述PD患者炎症的临床原因,以便未来可能针对这些原因制定潜在策略。